Loading company…
San Diego-based Neurelis develops treatments for neurological conditions, including the VALTOCO nasal spray for epilepsy.
Neurelis, Inc. develops treatments for neurological conditions, mainly epilepsy. Its VALTOCO product is a nasal spray for the rapid treatment of seizure clusters, built on proprietary Intravail, ProTek and Hydrogel technologies. Founded in 2007 by Craig Chambliss and based in San Diego, US, the company completed nine deals, most recently an agreement by Biotie Therapies Corp. to acquire it on June 4, 2013, with terms undisclosed. Its Series D round raised USD 114.76 mn, with investors including Cormorant Asset Management and Decheng Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in